Brief: Mineralys Therapeutics Announces Positive Topline Results From Phase 2 Trial Of Lorundrostat For The Treatment Of Hypertension
17/06/2025 12:38
June 17 (Reuters) - Mineralys Therapeutics Inc MLYS.O: MINERALYS THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 EXPLORE-CKD TRIAL OF LORUNDROSTAT FOR THE TREATMENT OF HYPERTENSION IN SUBJECTS WITH CKD AND ALBUMINURIA MINERALYS THERAPEUTICS INC - LORUNDROSTAT DEMONSTRATES FAVORABLE SAFETY AND TOLERABILITY PROFILE MINERALYS THERAPEUTICS INC - SERIOUS ADVERSE EVENTS REPORTED IN 3% OF SUBJECTS DURING LORUNDROSTAT TREATMENT MINERALYS THERAPEUTICS INC - LORUNDROSTAT 25 MG ACHIEVES 9.3 MMHG REDUCTION IN SYSTOLIC BLOOD PRESSURE MINERALYS THERAPEUTICS INC - LORUNDROSTAT SHOWS 31% REDUCTION IN URINE ALBUMIN-TO-CREATININE RATIO MINERALYS THERAPEUTICS INC - ONE SUBJECT DISCONTINUED LORUNDROSTAT DUE TO ELEVATED POTASSIUM Source text: ID:nGNX30bH7v Further company coverage: MLYS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mineralys Therapeutics
See all newsBrief: Mineralys Therapeutics Expands Its Board Of Directors With The Appointments Of Kristine Peterson And Lonnel Coats
Mineralys Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway